A novel PDE10A inhibitor just showed safety and efficacy in a large Phase 2 trial for acute schizophrenia. 👏
📌 PDE10A inhibitors represent a non-dopaminergic approach—targeting phosphodiesterase 10A to modulate both D1 and D2 pathways indirectly. This could be a game-changer for patients who don’t respond to or can’t tolerate traditional D2 blockers.
🔍 The trial demonstrated:
✅ Significant reduction in PANSS total scores
✅ Favorable side effect profile (no EPS or prolactin elevation)
✅ Oral formulation, once daily
This reinforces the urgent need to diversify our treatment mechanisms beyond dopamine antagonism. As treatment-resistant schizophrenia remains a major challenge, we’ll take all the innovation we can get.
🧠 Stay tuned—PDE10A could join the ranks of TAAR1 agonists and muscarinic agents in reshaping how we treat serious mental illness.